NHS Rejects Donanemab and Lecanemab in Final Draft Alzheimer’s Guidance
NICE has released final draft guidance stating that two new Alzheimer’s treatments, donanemab and lecanemab, offer limited benefit and are...
Access our range of useful resources here, including Choice and Medication & clinical guidelines
Filter: